Literature DB >> 21136783

Proteomic characterization of differentially expressed proteins in breast cancer: Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu status.

Daohai Zhang1, Lee Kian Tai, Lee Lee Wong, Thomas C Putti, Sunil K Sethi, Ming Teh, Evelyn S C Koay.   

Abstract

The human epidermal growth factor receptor type 2 (HER-2/neu) oncoprotein is overexpressed in about 30% of breast cancers and associates with metastatic phenotypes of breast tumours. Dissecting the HER-2/neu-modulated molecules in cancer will be helpful in elucidating the underlying molecular mechanisms of HER-2/neu-driven tumourigenesis. We investigated the differential proteome profiles between microdissected HER-2/neu-positive and -negative tumours and unambiguously identified 21 proteins with diverse biological functions by peptide sequencing and NCBInr database interrogation. Six proteins were up-regulated whereas 15 were down-regulated in the HER-2/neu-positive tumours. Differential expressions of heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1), 78 kDa glucose-regulated protein (GRP78/Bip) and Raf-1 kinase inhibitor protein (RKIP), which have not been previously reported as being linked to HER-2/neu signalling, were further verified. Immunohistochemical staining on tissue microarray sections demonstrated a positive correlation of hnRNP H1 (p = 0.008) and negative correlations of GRP78 and RKIP (p = 0.018 and 0.013, respectively) with HER-2/neu. Heregulin α1 enhanced hnRNP H1, but reduced GRP78 and RKIP expression in BT474 cells in a dose-dependent manner, providing evidence of crosstalk between HER-2/neu signalling and these modulators. Our studies have identified novel modulators that are likely to be intricately involved in HER-2/neu-driven tumour proliferation, invasion and metastasis.
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2008        PMID: 21136783     DOI: 10.1002/prca.200780099

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  6 in total

1.  Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance.

Authors:  Michal Stark; Eran E Bram; Martin Akerman; Yael Mandel-Gutfreund; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

Review 2.  TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.

Authors:  Kojo Agyemang; Allan M Johansen; Grayson W Barker; Michael J Pennison; Kimberly Sheffield; Hugo Jimenez; Carl Blackman; Sambad Sharma; Patrick A Fordjour; Ravi Singh; Katherine L Cook; Hui-Kuan Lin; Wei Zhang; Hui-Wen Lo; Kounosuke Watabe; Peiqing Sun; Carl D Langefeld; Boris Pasche
Journal:  NPJ Breast Cancer       Date:  2022-07-19

3.  Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer.

Authors:  Fahd Al-Mulla; Milad S Bitar; Jean Paul Thiery; Tan Tuan Zea; Devasis Chatterjee; Lindsay Bennett; Sungdae Park; Joanne Edwards; Kam C Yeung
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

4.  Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.

Authors:  Liang Zhao; Hongdan Li; Yijie Shi; Guan Wang; Liwei Liu; Chang Su; Rongjian Su
Journal:  Int J Nanomedicine       Date:  2014-12-30

Review 5.  The Unfolded Protein Response in Breast Cancer.

Authors:  Eoghan P McGrath; Susan E Logue; Katarzyna Mnich; Shane Deegan; Richard Jäger; Adrienne M Gorman; Afshin Samali
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

6.  Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer.

Authors:  Alfredo Toledo-Leyva; Julio César Villegas-Pineda; Sergio Encarnación-Guevara; Dolores Gallardo-Rincón; Patricia Talamás-Rohana
Journal:  Proteome Sci       Date:  2018-02-13       Impact factor: 2.480

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.